A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01465386

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:37.379411+00:00

Published At

2017-04-04T00:00:00+00:00

Record Updated At

2017-04-04

Results Posted At

2017-04-04

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Promyelocytic Leukemia (M3)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Secondary Acute Myeloid Leukemia"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2017-04-04"

protocolSection.identificationModule.nctId

"NCT01465386"

protocolSection.identificationModule.officialTitle

"A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2017-04-04"

Study condition terms

• Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
• Adult Acute Minimally Differentiated Myeloid Leukemia (M0) (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloblastic Leukemia Without Maturation (M1) (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia in Remission (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With Del(5q) (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) (protocolSection.conditionsModule.conditions)
• Adult Acute Promyelocytic Leukemia (M3) (protocolSection.conditionsModule.conditions)
• Adult Erythroleukemia (M6a) (protocolSection.conditionsModule.conditions)
• Adult Pure Erythroid Leukemia (M6b) (protocolSection.conditionsModule.conditions)
• Secondary Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.